HEMEO announces its successful bridge funding round, marking a significant step forward in empowering clinicians with the needed tools and information to enable better treatment for patients.

Hemeo, the pioneering CDS platform company aimed at advancing patient hemostasis management, is thrilled to announce the successful completion of its bridge funding round, which was oversubscribed and secured $850,000. This round was led by NLC’s Health Impact Fund and was supported by US based Yahara Ventures and London based, BGO Software, along with continued contributions from existing investors. This milestone marks a significant step in Hemeo’s journey to be the global leader in preventing and treating thromboses and excess bleeding events, by continuing to build a profitable, value based, patient-centric company that assists physicians in advancing patient hemostasis management. 

“It was a wonderful funding round, led by a great combination of new and existing investors, all who see the amazing potential of HEMEO’s technology and who share HEMEO’s desire to accomplish its critical mission of saving lives,” said Lee DeGeer, Hemeo’s President and CEO.  “Not only does this funding allow Hemeo to finish its VANTAGE CDS platforms development, ensuring that it complies with the US FDA discretionary guidance on Software as a Medical Device, but it has also allowed us to add key personnel to the Hemeo family, in support of our pending commercial launch.”

Solving the Global Blood shortage one Patient at a Time

HEMEO has worked with over 20 of the world’s top anesthesiologists and intensivists, with each confirming the problem, unanimously endorsing our solution and committing  to bring in HEMEO’s VANTAGE product to their hospitals once it is fully developed.

“With blood being a finite and expensive resource, we need to practice proper stewardship to prevent overuse,” says Daryl Kor, M.D., an anesthesiologist and Medical Director of Patient Blood Management at Mayo Clinic. “Current studies* indicate that 40 to 60 percent of transfusions are deemed unnecessary or avoidable.”**

HEMEO’s Mission, Vision and Objectives

• Mission – is to save lives and improve patient outcomes, by enabling physicians to prevent and treat harmful and costly bleeding and thrombosis events.
• Vision – to be the global leader in preventing and treating thromboses and bleeding, by building a profitable, value based, patient-centric company that assists the care team in advancing patient hemostasis management.
• Key upcoming Objectives –
  • Vantage Product in final development – initial application in Cardiac Surgery for the US Market.
  • Next funding round – full SEED round @ $3 million USD via a SAFE agreement
  • Mid-year 2025 – Planned Commercial Launch of Vantage in US and Canada

Featured in the Media

Read more about HEMEO in this article in Forbes magazine.

About HEMEO

HEMEO is a medical software company that provides AI-based clinical decision support applications to clinicians. We focus the power of artificial intelligence into data management applications, enabling effective administration, processing, and sharing of hemostasis and coagulation data throughout the healthcare enterprise.

We aspire to pave the way for a future where access to high-quality care is universal, where inefficiencies and variations in care are eradicated and where the healthcare experience is streamlined and personalized. We do this by providing physicians with an AI-based Clinical Decision Support software platform for blood management during cardiac and other critical surgeries.

HEMEO Vantage provides one consolidated view and will promote consistent, appropriate decision making and will reduce patient bleeding and reduce transfusion costs up to 10%, as out of range values are highlighted and timely, patient applicable guidance is provided.  It is highly configurable to seamlessly integrate with the local way-of-working.

HEMEO Vantage with AI, will add a growing repertoire of continuously improving AI algorithms, enabling personalized treatment decisions and continue to reduce patient bleeding and reduce transfusion costs by up to 30%. Hemeo’s technology creates a “digital twin” of the human coagulation system and will predict highly accurate bleeding risk indications, provide personalized treatment recommendations and will shift focus from bleeding treatment to bleeding prevention. Essentially it personalizes the hemostasis process for the individual patient.

*Shander A, Fink A, Jividroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev. 2011 Jul;25(3):232-246.e53

**https://newsnetwork.mayoclinic.org/discussion/mayo-medical-laboratories-national-decision-support-company-team-up-to-develop-careselect-blood-a-comprehensive-approach-to-patient-blood-management/